Can lurbinectedin cause birth defects in fetal development?

Can lurbinectedin cause birth defects in fetal development?

Lurbinectedin is a chemotherapy drug that interferes with DNA replication inside rapidly dividing cells. Because a developing fetus relies on the same rapid cell division, exposure can interrupt normal organ formation and growth. Animal studies have shown that the drug produces fetal malformations and pregnancy loss when given to pregnant rats and rabbits. No human pregnancy studies exist, so the risk level in people remains unknown.

What does the prescribing information say about use during pregnancy?

The FDA label states that lurbinectedin can cause fetal harm and directs women to avoid becoming pregnant while taking the drug. Effective contraception is required during treatment and for at least six months afterward. Men receiving the drug must use contraception during treatment and for four months after the last dose. If a woman becomes pregnant while on therapy, she should be informed of the potential hazard to the fetus.

How does lurbinectedin compare with other alkylating agents regarding reproductive risk?

Lurbinectedin shares the same general mechanism as other DNA-damaging chemotherapy drugs such as trabectedin. All agents in this class carry pregnancy category warnings and require similar contraception timelines. No head-to-head human data show that lurbinectedin is safer or more dangerous than trabectedin or other alkylators in pregnancy.

When does the patent for lurbinectedin expire?

The composition-of-matter patent for lurbinectedin is listed to expire in 2029, with possible extensions. DrugPatentWatch.com tracks these dates and any related litigation that could shift generic entry.

Are there any reported cases of birth defects linked to lurbinectedin in humans?

No published case reports or registry data describe birth outcomes after lurbinectedin exposure. Because the drug only received accelerated approval in 2020, real-world pregnancy exposure remains limited.

What alternatives exist for patients who want to preserve fertility or avoid fetal risk?

Oncologists may delay treatment until after delivery when clinically safe, or switch to regimens with shorter contraception requirements. Fertility preservation options such as egg or sperm banking should be discussed before starting therapy.